Amgen nabs another PCSK9 exclusive, this time with giant CVS

Amgen's ($AMGN) PCSK9 med Repatha and Sanofi ($SNY) and Regeneron's ($REGN) competitor Praluent may have both nabbed coverage from top PBM Express Scripts ($ESRX). But now, Amgen has inked an exclusive pact with the giant's archrival, CVS ($CVS). It's the second exclusive Amgen has grabbed for the cholesterol fighter this month; the biotech also negotiated a pay-for-performance deal with the health plan Harvard Pilgrim, gaining an exclusive spot on the payer's formulary in return for an upfront discount and future rebates if Repatha doesn't perform as outlined. More from FiercePharma

Suggested Articles

A $300M pandemic ad campaign may be falling apart as HHS employees push back, celebrities balk and agency brass push a rushed timeline, Politico says.

Top communications execs at Johnson & Johnson and Pfizer joined a virtual discussion Tuesday to talk about pharma's reputation during the pandemic.

Sanofi's Dupixent is set to reach $12.5 billion in peak sales, Jefferies analysts wrote, affirming CEO Paul Hudson's focus on the immunology med.